
NASDAQHealthcareMedical - Devices
Latest quote
$9.29
−$0.02 · -0.21%
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Previous close
$9.29
−$0.02 · -0.21%
Regular session · ET · Market data may be delayed.
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Day range
Current $9.29
52-week range
Current $9.29
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
64
Undervalued
Sentiment
68
Bullish
Risk
57
Elevated Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Day range
Current $9.29
52-week range
Current $9.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 822.31M USD | 799.49M USD | 746.64M USD | 460.71M USD | 464.48M USD |
| Cost of goods sold | 270.61M USD | 253.61M USD | 260.37M USD | 123.54M USD | 114.91M USD |
| Gross profit | 551.71M USD | 545.89M USD | 486.27M USD | 337.17M USD | 349.57M USD |
| Research and development | 57.11M USD | 73.64M USD | 80.23M USD | 49.07M USD | 49.62M USD |
| Selling, general, and administrative | 456.39M USD | 532.53M USD | 530.4M USD | 308.78M USD | 290.67M USD |
| Operating expenses | 620.18M USD | 630.5M USD | 625.38M USD | 350.44M USD | 357.88M USD |
| Interest expense | 17.49M USD | 29.63M USD | 8.63M USD | 1.29M USD | 1.84M USD |
| Depreciation and amortization | 50.97M USD | 60.06M USD | 60.56M USD | 32.08M USD | 33.1M USD |
| Operating income | −68.47M USD | −84.62M USD | −139.11M USD | −13.27M USD | −8.32M USD |
| Net income | −92.19M USD | −126M USD | −151.4M USD | −19.75M USD | −38.38M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI14.33M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM9.57M0.01%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF5.6M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN3.39M0.02%14.47B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO2.67M0.01%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA1.85M0.01%22.56B USD0.03%$34.55+1.01%
iShares U.S. Medical Devices ETFIHI1.83M0.05%3.42B USD0.37%$53.63-0.52%
Fidelity Enhanced Small Cap ETFFESM1.44M0.02%6.03B USD0.28%$47.36+0.21%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHI
Fidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.